On June 29, Liquidia Technologies rose 5.96% in pre-market trading, trading at $80.97/share, with turnover of approximately $51,100.

The rally is driven by continued strong commercialization momentum of the company's core product YUTREPIA combined with an upcoming academic conference catalyst. The company reported Q1 net product sales of approximately $130 million with over 4,500 unique patient prescriptions, swinging to profitability with EPS of $0.52, significantly beating the consensus estimate of $0.41. This represents a 215.56% improvement from a loss of $0.45 per share in the year-ago quarter. Multiple analysts subsequently raised their price targets following the Q1 results.

Additionally, the company announced on June 11 that it will present poster data at the PHA 2026 International Pulmonary Hypertension Conference, providing further near-term catalyst. The combination of accelerating revenue growth, profitability inflection, and scientific data disclosure continues to support bullish sentiment around the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)